GSK plc (NYSE:GSK) on Tuesday agreed to accumulate RAPT Therapeutics Inc. (NASDAQ:RAPT) for $58.00 per share.
The deal consideration is equal to an estimated combination fairness worth of $2.2 billion. Internet of money acquired, GSK’s estimated upfront funding is $1.9 billion.
RAPT Therapeutics is a California-based, clinical-stage biopharmaceutical firm devoted to creating novel therapies for inflammatory and immunologic illnesses.
The acquisition consists of ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody, presently in section 2b medical improvement for prophylactic safety in opposition to meals allergens.
IgE is a clinically validated goal and is the one accredited systemic remedy proven to guard sufferers from a dangerous allergic and inflammatory immune response. Round 94% of extreme meals allergic reactions are attributable to IgE-mediated reactions.
Present anti-IgE therapy for meals allergy entails injections each 2 to 4 weeks. Ozureprubart’s medical profile gives the potential for much less frequent dosing each 12 weeks, supporting improved compliance and affected person outcomes, in addition to offering a brand new choice to roughly 25% of sufferers presently ineligible for present remedy. Ozureprubart enhances GSK’s intensive industrial footprint and prescriber base in allergy.
Knowledge from the section 2b trial (prestIgE) assessing the usage of ozureprubart as monotherapy is anticipated in 2027, with section 3 trials to be targeted on each at-risk grownup and paediatric populations.
Massive and Rising Meals Allergy Market
Within the U.S., over 17 million individuals are identified with meals allergic reactions, with greater than 1.3 million folks struggling extreme reactions. Greater than 3 million affected person visits annually to the hospital and emergency care.
The transaction provides GSK the worldwide rights to the ozureprubart program, excluding mainland China, Macau, Taiwan, and Hong Kong. GSK will even be chargeable for success-based milestone and royalty funds for ozureprubart owed to RAPT’s accomplice, Shanghai Jeyou Pharmaceutical Co., Ltd.
Administration Commentary
Tony Wooden, GSK’s chief scientific officer, stated ozureprubart strengthens the corporate’s pipeline with a possible best-in-class allergy therapy, providing longer-lasting safety with quarterly dosing and addressing a transparent unmet want in meals allergy care.
RAPT Therapeutics CEO Brian Wong stated the deal provides ozureprubart a transparent path ahead, pairing this system with GSK’s international improvement and industrial scale to unlock better worth for sufferers and shareholders.
Pfizer Exits ViiV Healthcare Stake
Concurrently, Pfizer Inc. (NYSE:PFE) agreed to exit its 11.7% funding in HIV drug developer, ViiV Healthcare.
With the transaction, Shionogi Co. Ltd.’s holding will increase to 21.7%, and GSK maintains the 78.3% majority share.
ViiV Healthcare will difficulty new shares to Shionogi for $2.125 billion, and Pfizer will obtain $1.875 billion.
GSK will obtain a particular dividend of $250 million, payable in GBP.
Shionogi will proceed to have one Director place on the ViiV Healthcare Board, and will probably be represented by Dr John Keller, who has been a Director of ViiV Healthcare since 2012.
Each transactions are anticipated to shut within the first quarter of 2026.
Worth Motion: RAPT Therapeutics shares had been up 63.53% at $57.40 throughout premarket buying and selling on Tuesday. The inventory is buying and selling at a brand new 52-week excessive, based on Benzinga Professional information. GSK shares had been up 0.04%. Pfizer shares had been down 0.51%.
Picture by HJBC by way of Shutterstock